Although most people can get rid of the disease through a course of antibiotics, some suffer for years with persistent symptoms.
VLA15 is given in three doses that are and then an additional booster. Half of the participants will be given placebo saline for the first three doses, and half will receive the saline-based placebo as an extra dose The company stated.
The vaccine is a targeted attack on an outer layer protein in Borrelia burgdorferi bacteria, which causes Lyme disease. Blocking this protein may hinder the ability of the bacteria to leap from person to tick.
In the earlier tests, both in individuals and in labs and in labs, this vaccine “demonstrated a strong immune response and satisfactory safety profile,” the companies stated.